The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美国食品药品管理局批准了 C4 Therapeutics 针对非小细胞肺癌的 CFT8919 的研究性新药申请；在贝达制药完成大中华区 1 期剂量递增研究后，C4T 预计将在大中华区以外启动试验
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美国食品药品管理局批准了 C4 Therapeutics 针对非小细胞肺癌的 CFT8919 的研究性新药申请；在贝达制药完成大中华区 1 期剂量递增研究后，C4T 预计将在大中华区以外启动试验